Cancer is a disease caused by the alteration of proto-oncogenes and tumor suppressor genes, which has a high prevalence in the population and is one of the main causes of death worldwide. For its treatment, there are different therapy options, but these are not always effective for all existing types of cancer, which gives rise to the search for new compounds. The objective of the work is to determine the degree of cytotoxic activity of naphthoxyacetamide using dose-response curves in a cell viability assay. For this, the cytotoxic effects of N-(2-morpholinoethyl)-2-(naphthalen-2-yloxy) were identified in cancer cells (HeLa) based on the metabolic reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylretrazol (MTT) bromide. The cell cultures were seeded at a density of 5,000 cells/well in 96-well plates and treated by hexapplication with various concen-trations of the compounds to be tested (0.31-3.16 µM/mL) for 24 h. Microplates were read in an ELISA reader at 575nm. The dose response curve of N- (2-morpholinoethyl)-2-(naphthalen-2-yloxy)acetamide (3.16, 1.77, 1, 0.31 µM/mL). The results showed that N-(2-morpholinoethyl)-2-(naphthalen-2-yloxy)acetamide, at a concentration of 3.16 µM/ mL, presents cytotoxic effects similar to those shown by the drug reference (cisplatin 3.32 µM/mL). In conclusion, N-(2-morpholinoethyl)-2-(naphthalen-2-yloxy)acetamide showed cyto-toxic effects similar to Cisplatin.